Résumé
Cell-based therapies, defined here as the delivery of cells in vivo to treat disease, have recently gained increasing public attention as a potentially promising approach to restore structure and function to musculoskeletal tissues. Although cell-based therapy has the potential to improve the treatment of disorders of the musculoskeletal system, there is also the possibility of misuse and misrepresentation of the efficacy of such treatments. The medical literature contains anecdotal reports and research studies, along with web-based marketing and patient testimonials supporting cell-based therapy. Both the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) are committed to ensuring that the potential of cell-based therapies is realized through rigorous, reproducible, and clinically meaningful scientific discovery. The two organizations convened a multidisciplinary and international Task Force composed of physicians, surgeons, and scientists who are recognized experts in the development and use of cell-based therapies. The Task Force was charged with defining the state-of-the art in cell-based therapies and identifying the gaps in knowledge and methodologies that should guide the research agenda. The efforts of this Task Force are designed to provide researchers and clinicians with a better understanding of the current state of the science and research needed to advance the study and use of cell-based therapies for skeletal tissues. The design and implementation of rigorous, thorough protocols will be critical to leveraging these innovative treatments and optimizing clinical and functional patient outcomes. In addition to providing specific recommendations and ethical considerations for preclinical and clinical investigations, this report concludes with an outline to address knowledge gaps in how to determine the cell autonomous and nonautonomous effects of a donor population used for bone regeneration.
Langue d'origine | English |
---|---|
Pages (de-à) | 485-502 |
Nombre de pages | 18 |
Journal | Journal of Orthopaedic Research |
Volume | 38 |
Numéro de publication | 3 |
DOI | |
Statut de publication | Published - mars 1 2020 |
Financement
The Task Force members would like to thank Fei Wang, Ph.D. from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) for serving as an Advisory Liaison. We also express our appreciation to the late Paolo Bianco, M.D. and Christopher R. Jacobs, Ph.D., whose contributions to this work were of great significance. The Task Force would also like to acknowledge the dedicated staff of the ASBMR, particularly Mr. Doug Fesler and Ms. Lynn Mirigian, without whose enthusiastic participation and administrative skills this Task Force report would not have been possible. ROK is an Advisory Board member of the International Academic Advisory Board and the Arthritis Board of the University Health Network of the University of Toronto. RT is a member of the Advisory Board for Orthocell, Perth, Western Australia. LF has received consulting fees from Arthrex Inc. VR is a consultant for Keros Therapeutics Inc. and CollPlant Inc. ES is an Advisory Board Member of LAGeT Inc.; the Owner, Founder, and Chief Scientific Officer of Telephus Biosciences; has received fees for expert witness testimony; and has received research support from Janssen J&J Inc., Lily, Amedica Inc., and Amgen. DL is a consultant for OrthoPediatrics and has received research grants from Novartis, Amgen, and Celgene. RG is a consultant and has stock holdings for Restor3D Inc., MiMedx Inc., and Medicus Biosciences Inc.; FB is a shareholder in Osiris Therapeutics Inc. and a Shareholder and Director in Orbsen Therapeutics Inc. SR is a consultant and has stock options in Ortho Regenerative Technologies Inc., has received research support from Angiocrine Bioscience, and is a consultant for Advance Medical. NN is a consultant and has stock option in Two Cells Inc. and Cell Source Inc. BP is a Consultant or member of advisory board for MIACH Orthopaedics. All other authors have no conflicts to disclose.
Bailleurs de fonds | Numéro du bailleur de fonds |
---|---|
National Institute of Arthritis and Musculoskeletal and Skin Diseases | R01AR072707 |
Amgen | |
Novartis | |
Celgene |
ASJC Scopus Subject Areas
- Orthopedics and Sports Medicine